Glaucoma costs to double by 2025

Article

A new study shows that costs associated with glaucoma will more than double by 2025.

A new study shows that costs associated with glaucoma will more than double by 2025. The Australian study has estimated costs in the country to reach AUS$4.3 billion (around E2.6 billion) by 2025, more than double the total cost in 2005.

The report, "Tunnel Vision: the Economic Impact of Primary Open Angle Glaucoma", released by the Centre for Eye Research Australia and Access Economics, showed costs associated with glaucoma totalled AUS$1.9 billion in 2005. The report recommends changes to current practice to reduce the projected 2025 costs, including a public health awareness campaign. Of the 300 000 Australians living with glaucoma, half of these are currently unaware that they have the condition; late diagnosis is associated with increased cost of treatment due to extensive disease progression.

The report's recommended measures also include conducting studies to compare laser treatments with traditional glaucoma therapies and research into better understanding the pathophysiology of glaucoma, leading to the development of new, more cost-effective treatments.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.